EA201692220A1 - Твердые формы противовирусного соединения - Google Patents
Твердые формы противовирусного соединенияInfo
- Publication number
- EA201692220A1 EA201692220A1 EA201692220A EA201692220A EA201692220A1 EA 201692220 A1 EA201692220 A1 EA 201692220A1 EA 201692220 A EA201692220 A EA 201692220A EA 201692220 A EA201692220 A EA 201692220A EA 201692220 A1 EA201692220 A1 EA 201692220A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solid forms
- virus compound
- imidazol
- methyl
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 230000002155 anti-virotic effect Effects 0.000 title 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010919P | 2014-06-11 | 2014-06-11 | |
| PCT/US2015/034649 WO2015191431A1 (en) | 2014-06-11 | 2015-06-08 | Solid forms of an antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201692220A1 true EA201692220A1 (ru) | 2017-05-31 |
Family
ID=53443009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201692220A EA201692220A1 (ru) | 2014-06-11 | 2015-06-08 | Твердые формы противовирусного соединения |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9630972B2 (enExample) |
| EP (3) | EP3154983B1 (enExample) |
| JP (3) | JP2017517532A (enExample) |
| KR (3) | KR20170015506A (enExample) |
| CN (1) | CN106661042A (enExample) |
| AR (1) | AR103194A1 (enExample) |
| AU (2) | AU2015274961A1 (enExample) |
| BR (1) | BR112016028843A2 (enExample) |
| CA (1) | CA2951188C (enExample) |
| EA (1) | EA201692220A1 (enExample) |
| ES (1) | ES2785409T3 (enExample) |
| IL (1) | IL249041A0 (enExample) |
| MX (1) | MX2016016299A (enExample) |
| PL (1) | PL3154983T3 (enExample) |
| PT (1) | PT3154983T (enExample) |
| SG (1) | SG11201609810YA (enExample) |
| SI (1) | SI3154983T1 (enExample) |
| TW (1) | TWI721947B (enExample) |
| WO (1) | WO2015191431A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2604620T2 (sl) | 2003-05-30 | 2024-10-30 | Gilead Pharmasset Llc | Modificirani fluorirani nukleozidni analogi |
| CA3095528C (en) | 2010-11-17 | 2023-07-18 | Gilead Pharmasset Llc | Antiviral compounds |
| UA119437C2 (uk) | 2011-11-16 | 2019-06-25 | Гайлід Фармассет Елелсі | Противірусні сполуки |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| CN108368123B (zh) * | 2016-07-08 | 2021-02-19 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑基化合物及其药物组合物 |
| CN106432253B (zh) * | 2016-09-21 | 2019-06-14 | 上海众强药业有限公司 | 一种维帕他韦新晶型及其制备方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| JPWO2004089933A1 (ja) * | 2003-04-02 | 2006-07-06 | アステラス製薬株式会社 | フルオロベンズアミド誘導体の新規結晶 |
| JP4584909B2 (ja) | 2003-05-09 | 2010-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスｎｓ５ｂポリメラーゼインヒビター結合ポケット |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| KR100853601B1 (ko) | 2004-09-22 | 2008-08-22 | 화이자 인코포레이티드 | 8-플루오로-2-｛4-[(메틸아미노)메틸]페닐｝-1,3,4,5-테트라하이드로-6Ｈ-아제피노[5,4,3-ｃｄ]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태 |
| BRPI0711556A2 (pt) * | 2006-05-05 | 2011-11-08 | Merck Patent Gmbh | fosfato de (3-ciano-1h-indol-7-il)-[4-(4-fluorofenetil)piperazin-1-i l]metanona cristalina |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2009286694A (ja) | 2006-09-07 | 2009-12-10 | Eisai R & D Management Co Ltd | ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶 |
| CA2823981C (en) | 2006-12-07 | 2016-05-17 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2514517T3 (es) * | 2007-08-10 | 2014-10-28 | Mitsubishi Tanabe Pharma Corporation | Nueva sal de compuesto de isoquinolina y cristal de la misma |
| NZ587323A (en) | 2008-02-12 | 2012-02-24 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2008350334B2 (en) | 2008-02-13 | 2013-10-17 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2323631A1 (en) | 2008-08-07 | 2011-05-25 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| HK1203929A1 (en) | 2008-12-03 | 2015-11-06 | 普雷西迪奥制药公司 | Inhibitors of hcv ns5a |
| JP2012510523A (ja) | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| CA2753313A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| PL2410844T3 (pl) | 2009-03-27 | 2016-08-31 | Merck Sharp & Dohme | Inhibitory replikacji wirusa zapalenia wątroby typu c |
| CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| CA2755658A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis c |
| AU2010249080A1 (en) | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| HUE036906T2 (hu) | 2009-05-13 | 2018-08-28 | Antivirális vegyületek | |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012002759A (es) | 2009-09-04 | 2012-04-30 | Glaxosmithkline Llc | Compuestos quimicos. |
| EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| AR080676A1 (es) | 2010-03-09 | 2012-05-02 | Schering Corp | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| KR101894704B1 (ko) | 2010-09-21 | 2018-09-05 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제 |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CA3095528C (en) | 2010-11-17 | 2023-07-18 | Gilead Pharmasset Llc | Antiviral compounds |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| UA119437C2 (uk) | 2011-11-16 | 2019-06-25 | Гайлід Фармассет Елелсі | Противірусні сполуки |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| HK1201186A1 (en) | 2011-12-29 | 2015-08-28 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| KR20140098706A (ko) | 2013-01-31 | 2014-08-08 | 닛토덴코 가부시키가이샤 | 에폭시 조성물 및 에폭시 수지 성형품 |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
| EP3588013A1 (de) | 2018-06-26 | 2020-01-01 | XelectriX Power GmbH | Verfahren zur abgabe von elektrischer energie |
-
2015
- 2015-05-28 TW TW104117182A patent/TWI721947B/zh active
- 2015-06-08 US US14/733,101 patent/US9630972B2/en active Active
- 2015-06-08 EP EP15730621.8A patent/EP3154983B1/en active Active
- 2015-06-08 KR KR1020177000696A patent/KR20170015506A/ko not_active Ceased
- 2015-06-08 SI SI201531097T patent/SI3154983T1/sl unknown
- 2015-06-08 KR KR1020207036803A patent/KR20200145852A/ko not_active Ceased
- 2015-06-08 CA CA2951188A patent/CA2951188C/en active Active
- 2015-06-08 PL PL15730621T patent/PL3154983T3/pl unknown
- 2015-06-08 EA EA201692220A patent/EA201692220A1/ru unknown
- 2015-06-08 SG SG11201609810YA patent/SG11201609810YA/en unknown
- 2015-06-08 KR KR1020197001272A patent/KR20190007533A/ko not_active Ceased
- 2015-06-08 MX MX2016016299A patent/MX2016016299A/es unknown
- 2015-06-08 EP EP20155444.1A patent/EP3666775A1/en not_active Withdrawn
- 2015-06-08 WO PCT/US2015/034649 patent/WO2015191431A1/en not_active Ceased
- 2015-06-08 PT PT157306218T patent/PT3154983T/pt unknown
- 2015-06-08 EP EP20213940.8A patent/EP3822275A1/en not_active Withdrawn
- 2015-06-08 BR BR112016028843A patent/BR112016028843A2/pt not_active IP Right Cessation
- 2015-06-08 JP JP2016572253A patent/JP2017517532A/ja not_active Withdrawn
- 2015-06-08 CN CN201580031460.3A patent/CN106661042A/zh active Pending
- 2015-06-08 ES ES15730621T patent/ES2785409T3/es active Active
- 2015-06-08 AU AU2015274961A patent/AU2015274961A1/en not_active Abandoned
- 2015-06-10 AR ARP150101835A patent/AR103194A1/es unknown
-
2016
- 2016-11-17 IL IL249041A patent/IL249041A0/en unknown
-
2017
- 2017-03-15 US US15/459,785 patent/US9884873B2/en active Active
- 2017-12-18 US US15/845,837 patent/US10604530B2/en active Active
-
2018
- 2018-03-19 AU AU2018201948A patent/AU2018201948B2/en active Active
-
2019
- 2019-02-18 JP JP2019026534A patent/JP2019070057A/ja not_active Ceased
- 2019-07-19 JP JP2019133593A patent/JP2019172711A/ja active Pending
-
2020
- 2020-02-21 US US16/797,793 patent/US11203599B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201692220A1 (ru) | Твердые формы противовирусного соединения | |
| LT3184523T (lt) | N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui | |
| EA201890731A1 (ru) | Модуляторы корового белка гепатита b | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| LT3220916T (lt) | Vėžio gydymo n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5- (etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’- bifenil]-3-karboksamidu būdas | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA201690650A1 (ru) | Солевая форма гидрохлорида для ингибирования ezh2 | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201691440A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
| EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
| EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| EA201591512A1 (ru) | Борсодержащие молекулы, способы и составы | |
| CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| PE20151535A1 (es) | Derivado de dihidropiridazin-3,5-diona | |
| EA201591397A1 (ru) | Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса | |
| EA201491610A1 (ru) | Модуляторы x рецепторов печени | |
| EA201491007A1 (ru) | Лекарственные составы | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| MA39164B1 (fr) | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine | |
| UY34785A (es) | Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo | |
| EA201692550A1 (ru) | Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2 |